Growing Focus on Providing Equitable Access to Essential Healthcare Services to Every Patient to Drive Telehealth Market Growth

 

Telehealth can be defined as the delivery of healthcare services such as virtual visits, consultations, and remote monitoring through digital information and communication technologies such as mobile devices and computers. Telehealth has expanded the reach of medical services in remote and low-resource settings and has provided access to all across the globe. Telehealth leverages technology-based virtual platforms to deliver various aspects of health information, prevention, monitoring, and medical care. Over the recent past, telehealth has emerged as the fastest growing sector of healthcare with telemedicine at its core. Telemedicine can be defined as the practice of medicine through remote electronic interface. Telehealth aims to eliminate transportation costs that can be a burden to patients of low socioeconomic status and has the potential to improve health literacy by providing patient education and reduce hospitalization by promotion medication adherence.

One of the major applications of telehealth is the reduction of health disparities with limited access to physician. This could enable delivery of advanced healthcare facilities in rural areas where lesser number of physicians serve. In addition to improving access to healthcare facilities, telehealth is expected to reduce financial burdens on the health care systems of the countries. Telehealth and its related-technology can reduce referrals, streamline and optimize medical evaluations and tests, and reduce burden of certain preventable diseases. Increasing focus and emphasis on patient satisfaction, provision of efficient and quality care to patients, and minimal costs have led to large implementation of telehealth services. COVID-19 pandemic has significantly accelerated the adoption of telehealth services amid increasing concerns regarding risk of infections from face to face clinical interactions. Increasing research activities have been carried out to understand the impact of telehealth on the healthcare sector and its role in expanding access to healthcare facilities.

In a bid to understand other impacts of telehealth, researchers from the Ohio State University Wexner Medical Center in a May 2022 study found that telehealth appointments saved over 2.2 million gallons of gas for patients since the beginning of the pandemic. The Ohio State University Wexner Medical Center built a dashboard to estimate the impact of telehealth on the environment and through examination of reduced travel enabled by virtual visits, the researchers from the IT and sustainability team calculated use of gasoline and carbon emissions. The IT and sustainability team collaborated with a regional transportation authority to calculate the travel distance, usage of gasoline, and carbon emissions avoided by the patients.

Free Sample Copy Available@ https://www.emergenresearch.com/request-sample/893

In May 2022, MeMD, Walmart’s telehealth company, announced the launch of a virtual care diabetes program that is aimed at helping individuals improve diabetes management. The initiative is called the Walmart Health Virtual Care Diabetes Program and is developed for employers and payers as a standalone offering or a as a part of the comprehensive telehealth program. The program combines personalized diabetes education, behavioral health awareness and counselling, patients can connect with licensed medical provider to manage their lifestyle and symptoms. Main aim of the program is to identify and bridge the gaps in care and depression risks and allow scheduling of a follow-up visit with licensed behavioral health therapists to address each area of diabetes.   

Key companies operating in the telehealth market are investing heavily in developing robust telehealth platform to improve healthcare delivery and patient experience. Major companies operating in the market include Philips N.V. (Netherlands), Medtronic, GE Healthcare, Cerner Corporation, Siemens Healthineers, Cisco Systems, Inc., Teladoc Health Inc., American Well, AMC Health, MDLive, Doctor on Demand, Medvivo Group Ltd., Asahi Kasei Corporation, Iron Bow Technologies, Telespecialists LLC, GlobalMed, MedWeb, IMediplus Inc., Vsee, Chiron Health, and Zipnosis. In May 2022, The Department of Health and Human Services (HHS) announced award of USD 16.3 million to enhance and expand telehealth care and infrastructure and capacity of Title X Family planning clinics across 26 states, one U.S. territory, and one freely associated state.

Growing Importance of Biobanks in Advancing Medical Research and Discovery to Drive Biobanking Market Growth

 

Biobanking is the process by which samples of bodily fluids or tissues are collected for research purposes to advance understanding of health and diseases. Biobanks are large collections of human biological materials that are linked to relevant personal and health information and can include health records, family history, and lifestyle and genetic information, among others. Biobanks are considered as legal entities or parts of a legal entity that perform biobanking. Biobanking is the process of acquisitioning and storing along with other activities that are related to collection, preparation, and preservation and testing og define biological material and related information and data. Over the last decade, field of biobanking has rapidly grown alongside advancements in precision medicine and biobanks have been linked to advancement in screening and treating any disease, starting with cancer.

Modern biobanks allow large-scale analysis for assessing individual markers of specific diseases from biological or digital material with well-annotated clinical and biological data. These features play an important role in improving personalized medical approaches, where effective biomarker identification plays a crucial part in disease diagnosis and prognosis. Modern biobanks function as complex infrastructure where professionals such as clinicians, biologists, nurses, technicians, and bioethicists work together to guarantee the right to use human biological materials. Over the last few decades, technological advances such as automated sample processing, computerization, and the advent of internet revolutionized the management of biobanks. Biobanks can exist within research centers, hospitals, pharmaceutical companies, and patient advocacy organizations.

In a recent news, in April 2022, Al Jalila Foundation, which is a member of the Mohammed Bin Rashid Al Maktoum Global Initiatives, announced its plan to establish U.A.E.’s first robotic biobank in collaboration with Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) and the Dubai Health Authority (DHA). The partnership aims to advance medical research in the field of genetic disorders, cancer, and other chronic diseases and pandemics. The biobank is scheduled to open in 2023 with a capacity to manage and process seven million specimens and is set to be the largest biobank in terms of sample capacity in the world.

In a breakthrough study published in the journal Animals, it was suggested biobanking and assisted reproduction will help captive breeding programs to maintain genetic diversity and save koalas from extinction. This PhD research carried out at The University of Newcastle is the culmination of years spent in developing and analysing robust model of biobanking and assistive reproduction for various species that are endangered and was found to be more beneficial for koala bears.

Over the years, increasing advancements have been done to improve biobanking owing to a rapid surge in genomic research, regenerative medicines, and stem cell therapeutics. Major companies have invested in R&D and this has led to an increasing need for biobanking. Key companies in the market include K. Biobank Limited, Medizinische Universitat Graz, Hamilton Company, ASKION, Azenta Life Sciences, Qiagen, Promega Corporation, Integrated Biobank of Luxembourg (IBBL), Isenet Biobanking, and Thermo Fisher Scientific, Inc. In April 2021, Monash University launched first-of-its-kind industry focused storage facility for biological material in Australia. Biobanking Victoria is a state-of-the-art facility that aims to serve as a valuable link between researchers and industry and is backed by the Victorian Government.  

Growing Focus on Meeting the Urgent Clinical Need for More Efficacious Therapeutic Agents for Severe Diseases to Drive Immunocytokines Market Revenue Growth

 

Immunocytokines are fusion proteins that consist of a cytokine moiety that is fused to a monoclonal antibody or antibody fragments. On binding to the target antigen, cytokines are released directly into the tumor microenvironment, in turn, achieving high local concentrations with minimal systemic side effects. Immunocytokines represent a new and emerging class of biopharmaceuticals that demonstrate a high potential for cancer therapy and therapeutics for other chronic diseases. Immunocytokines have shown tremendous success in activating and redirecting effectors to human tumors and induce long-term antitumor immunity. Immunocytokines act as a robust vehicle for facilitating the delivery of an immune-stimulatory payload to selected cells or cells present at the disease sites.

Immunocytokines combine the desired elements of two excellent modalities of immunotherapy such as recombinant monoclonal antibody and cytokine therapy. Immunocytokines were developed to improve the benefits to risk ratio of monoclonal antibodies and cytokines alone or in combination. Use of antibody-cytokine fusion proteins has proven to have potential in improving the therapeutic index of cytokines by concentrating the payload at the site of disease without causing adverse off-target effects. One of the best examples of immunocytokines is the antibody-mediated targeted delivery of IL-12 that has shown at least 20 times more potent activity as compared to untargeted IL-12 in mouse model of cancer. Antibody-cytokine fusion proteins or immunocytokines are divided into two categories; large fusion proteins with cytokines fused to heavy chain of antibodies and small fusion proteins based on fragments of antibodies. Over the recent past, numerous immunocytokines have progressed to clinical trials as a potential and promising treatment for cancer. Currently, the immunocytokines that are underway in clinical trials are based on IgG format or on single chain variable fragment (scFv). In the recent years, use of immunocytokines has expanded from cancer therapy to the treatment of chronic inflammatory conditions and autoimmune diseases.

In a breakthrough study led by Tobias Weiss, a senior physician and research at the University Hospital Zurich, it was found that immunocytokines shown tremendous promise in the battle with glioblastoma. The study published in Science Translational Medicine, the researchers shared details on the effects of immunocytokines and revealed the immunocytokines delivered systemically showed effectiveness in mice models and pilot human trials. The team created three immunocytokines based on the L19 antibody, which is highly specific to extracellular matrix of glioblastoma tumor. The immunocytokines were intravenously injected in fully immunocompetant mice that were pretreated with orthotopic GL-261 gliomas. The treatment showed a stable safety profile and was effective in decreasing blood perfusion in the tumor and accelerated tumor necrosis.

In 2021, Nammi Therapeutics, Inc. which is a LA-based immunotherapy firm, unveiled first two cancer drug candidates; one from each of its distinctive drug development platforms called Nammisomes and Masked ImmunoCytokines at the American Association for Cancer Research Conference. Increasing number of companies are working towards development of robust immunocytokines for reshaping cancer treatment across the globe. In November 2021, Bright Peak Therapeutics, Inc., which is a prominent biotechnology company engaged in development of next-generation cytokine immunotherapies, announced a licensing agreement with Livzon Mabpharm, Inc. to use LZM009, Livzon’s proprietary anti-PD-1 monoclonal antibody that is currently in late-stage clinical trial, for the development of PD-1 targeted immunocytokines.

Major companies in the market include Alkermes Plc, AstraZeneca Plc, CytImmune Sciences, Cytune Pharma, Altor Bioscience Corporation, Apeiron Biologics AG, Paladin Labs, Teva Pharmaceutical Industries Ltd., Valor Biotherapeutics, and Targa Therapeutics Corporation. In April 2021, Bright Peak Therapeutics, Inc. and Ajinomoto Co., Inc., announced a research collaboration and licensing agreement for the development of immunocytokines. Bright Peak will be leveraging Ajinomoto’s AJICAP, a proprietary site-specific bioconjugation technology to develop immunocytokines molecules. In June 2021, Bright Peak Therapeutics, Inc., announced it had raised USD 107 million in a Series B round of funding which the company plans to use to expand its immunocytokine platform and advance its pipeline of programs across IL-2, IL-8, and IL-7.   

Increasing Focus on Developing Leading Edge Technology for Clinicians and Patients to Drive Growth of Next-Generation Ultrasound Market

 

Over the recent years, ultrasound imaging has evolved into an extremely versatile diagnostic tool that caters to every discipline of medical care. Ultrasound diagnostics are widely used in clinical settings due to its ability to acquire diagnostically relevant images, efficient translation of these images into diagnostic conclusions, and enabling cost-effective production of highly complex ultrasound imaging arrays that can capture 3D volumes. Advancements in electronics in the recent years have led to extraordinary refinement in all aspects of ultrasound systems. Researchers have been working towards finding out reliable ways to incorporate many individual transducers into compact arrays. 2D array can be focused throughout a volume to make a 3D image which can be done in real time. This capability can enhance ultrasound to next-level and over the coming years, can potentially allow robotic surgeons to operate on a beating heart, reducing the need to rely on a heart-lung machine during surgeries.

Next-generation ultrasound consisting 2D arrays of ultrasonic transducers can help physicians perform minimally invasive treatments enabling simultaneous ultrasound imaging and surgical therapy. As the computer technology evolves, ultrasound machines are expected to get faster and have more storage memory. Probes can get smaller and development of insertable probes will allow for a better imaging of internal organs. Over the recent past, extensive research activities have been carried out to develop ultrasound imaging in combination with AR/VR display that can allow physicians and surgeons to observe inside of the human body while performing minimally invasive or non-invasive procedures such as biopsy. Combination of deep learning technology and ultrasound imaging can create cost-effective and affordable 3D MEMS ultrasound platform technology that can potentially make the next-generation ultrasound device more personal, autonomous, and efficient in collecting and processing of data. Micro-electromechanical systems or MEMS have enabled researchers to develop capacitive micro-machine ultrasonic transducer that are mostly made of silicon.

Development of new diagnostic ultrasound methods have led to development of open platform ultrasound scanners that can effectively facilitate practical evaluation of new ultrasound imaging methods. In a recent news, Israel-based Sofwave Medical Ltd. developed a new treatment called Sofwave, which is a next-generation non-invasive aesthetic treatment that can help tackle signs of ageing to tone and lift the skin. The technology has been cleared by the U.S. FDA in November 2021, for lifting of the eyebrows, neck, cheeks, and reducing fine lines and wrinkles. Sofwave utilizes ultrasound heat to stimulate renewal of collagen deep within the skin. It leverages Intense Ultrasound Beam technology to generate heat at a specific depth in skin to promote collagen growth and elastin development in the mid-dermal layer. This helps in plumping the skin, thickening the layer to achieve tightening effect while making the skin look healthier.

Major companies in the Next-Generation Ultrasound market include Samsung Electronics Co. Ltd., General Electric Company, Canon Medical Systems Corporation, Hitachi Ltd., Siemens Healthineers AG, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., CHISON Medical Technologies Co. Ltd., Butterfly Network Inc., Medgyn Products Inc., and Claruis Mobile Health Corporation. In April 2022, Fujifilm Sonosite, Inc., which is a global leader in point-of-care ultrasound solutions (POCUS), announced a new addition to its next-generation POCUS portfolio, the new, premium Sonosite LX system that features the company’s clinical image and monitor that can extend, rotate, and tilt to enable enhanced and real-time provider collaboration.

Increasing Potential of Microneedle Patches as a Robust Tool for Transdermal Administration of Vaccine and Therapeutics to Drive Market Growth

Rapid advancements in nanotechnology have improved efficiency of microneedle patches through a shift from undissolving to dissolving microneedles. Microneedle patches can effectively deliver bioactive molecular of different physical size and hence are considered as robust drug delivery tools. Microneedle patches can also be coated or encapsulated with DNA vaccine, inactivated or live virus vaccine, and subunit antigen, among others. Microneedle patches have several advantages when used as drug and vaccine delivery vehicles such as pain-free and non-invasive route for reagent administration, no cold chain requirement for storage and transportation, low risk of needle-related injuries, and decrease in medical waste and transmission of blood-borne infectious diseases, particular in low-income and underdeveloped regions. Microneedle patches utilize the concept of microneedling to increase efficacy of active ingredients and use self-dissolving needles to penetrate the surface of the skin.

Microneedle patches, which are a highly efficient and versatile devices, have garnered extensive scientific and industrial attention over the past decade due to their attributes such as painless penetration, low cost, relative safety, and tremendous therapeutic efficacy. On the research front, microneedle patch has been used for minimally invasive evaluation of levels of inflammatory biomarkers and for efficient sampling of clavarial periosteum, which is a challenging site for biomarker detection, in mice. Use of microneedle patches for minimally invasive collection and analysis of biomarker levels in interstitial fluid has the potential to facilitate point-of-care (PoC) diagnostics and longitudinal monitoring. Increasing role of microneedles in revolutionizing the field of disease diagnosis and treatment, cosmetic applications, and immunobiological administration can open up new perspectives for development of advanced microneedles and contribute to revenue growth of the micro needle market.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/micro-needle-patch-market

In a recent research study published in Immunotherapy, researchers at Michigan Medicine partnered with Moonlight Therapeutics to develop 1 cm x 1 cm arrays of 50 microneedles each which measure 700 μm and each array is coated in formulation of peanut protein. The study was aimed at determining the efficacy of peanut-coated microneedle patches in peanut allergy while comparing the results of this approach with epicutaneous immunotherapy with peanut. The researchers inserted these peanut-coated microneedles into the hairless skin of female mice that were already sensitized to peanuts and held them in place for nearly 5 minutes to enable dissolution of protein inside the skin. The treatment was administered once a week for 5 weeks and results found that 90% mice that received PN-MN treatment developed no allergic responses. Moonlight Therapeutics in now planning first clinical trial of this approach in human volunteers and researchers believe microneedle treatment can provide a new frontier in enhancing cutaneous immunotherapy and improve administration of next-generation therapeutics for treating peanut and other food allergies.

In a breakthrough scientific study, researchers found that using 3D-printed microneedle patches for drug delivery resulted in enhanced cargo retention on the skin, robust activation of immune cells, and generation of more potent and cellular immune responses as compared with conventional vaccination routes. Similarly, a team of researchers and scientists from University of Queensland tested a COVID-19 vaccine patch that is capable of delivering pain-free dosage and eliminates the need for cold chain transport. The microneedle patch that can deliver COVID-19 DNA vaccine into the skin was found to induce strong immune responses in cells and mice. Researchers believe these advancements and applications of microneedle patches can potentially replace syringes over the coming years and is expected to drive market growth going ahead.

Prominent companies in the market include 3M Company, Becton Dickinson and Company, Zosano Pharma Corporation, Raphas Co. Ltd., Nanopass Tech, Corium International, Inc., Valeritas, Inc., Nitto Denko Corporation, Microdermics, Inc., Sanofi S.A. Recently, in April 2022, CGBIO, which is a total healthcare provider based in Seoul, South Korea, acquired a 12.3% stake in Daewoong Therapeutics, which is a bio-venture company that has developed a transdermal drug delivery system based on microneedle patches. The former is trying to develop cosmetics, medical devices, and medicine using microneedle technology and is expected to benefit from in-house technology of Daewoong Therapeutics.  

Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/993